Abstract
Background The neonatal immune system is uniquely poised to generate broadly neutralizing antibodies (bnAbs) and thus infants are ideal for evaluating HIV vaccine candidates. We present the design and safety of a novel glucopyranosyl lipid A (GLA)-stable emulsion (SE) adjuvant admixed with a first-in-infant CH505 transmitter-founder (CH505TF) gp120 immunogen designed to induce precursors for bnAbs against HIV.
Methods HVTN 135 is a phase I randomized, placebo-controlled trial of CH505TF+GLA-SE or placebo. Healthy infants in South Africa aged ≤5 days, born to mothers living with HIV but HIV nucleic acid negative at birth were randomized to five doses of CH505TF + GLA-SE or placebo at birth and 8, 16, 32, and 54 weeks.
Results 38 infants (median age = 4 days; interquartile range 4, 4.75 days) were enrolled November 2020 to January 2022. Among 28 (10) infants assigned to receive CH505TF + GLA-SE (placebo), most (32/38) completed the 5-dose immunization series and follow-up (35/38). Solicited local and systemic reactions were more frequent in vaccine (8, 28.6% local; 16, 57.1% systemic) vs. placebo recipients (1, 10% local, p = 0.25; 4, 40.0% systemic, p = 0.38). All events were Grade 1 except two Grade 2 events (pain, lethargy). Serious vaccine-related adverse events were not recorded.
Conclusions This study illustrates the feasibility of conducting trials of novel adjuvanted HIV vaccines in HIV-exposed infants receiving standard infant vaccinations. The safety profile of the CH505TF + GLA-SE vaccine was reassuring.
Trial registration ClinicalTrials.gov NCT04607408
Funding National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH)
Brief summary This paper summarizes the phase 1 trial design and safety profile of an experimental CH505TF immunogen + GLA-SE HIV vaccine in infants born to mothers living with HIV.
Competing Interest Statement
OL is a named inventor on patents relating to vaccine adjuvants and to human in vitro systems that model the safety and immunogenicity of adjuvants, vaccines and immunomodulators. He serves as a consultant to GSK and Hillevax and is a co-founder of Ovax, Inc. All other authors declare no conflict of interest.
Clinical Trial
NCT04607408
Funding Statement
The trial was funded through National Institute of Allergy and Infectious Disease of the National Institutes of Health under Grants UM1 AI068614 [HVTN Leadership and Operations Center], UM1 AI068635 [HVTN Statistical and Data Management Center], and UM1 AI068618 [HVTN Laboratory Center]. The members of the Precision Vaccines Program are supported in part via U.S. NIH/NIAID contracts and grants including Adjuvant Development Program Contract HHSN272201800047C (OL and KKS), U19 AI168643 Immune Development in Early Life (IDEAL; OL, KKS & AA), mentored clinical scientist development award 1K08AI168487 (AA), as well as a grant from HVTN (OL and KKS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was overseen by the University of the Witwatersrand Human Research Ethics Committee (HREC), reference number 190914B.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data sharing and availability
Participant follow-up is still underway. At study closeout, deidentified quality assured study data will be deposited at https://clinicaltrials.gov under accession number NCT04607408.
